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he emerging COVID-19 pandemic imposes a substantial
social and economic burden worldwide. The causative
agent of COVID-19 that causes, among other symptoms,
severe atypical pneumonia in humans was quickly identified as a
novel coronavirus and designated as SARS-CoV-21–4. Similar to
its closest homolog SARS-CoV-1, SARS-CoV-2 exploits the
ACE2 (angiotensin converting enzyme 2) receptor to enter host
cells5–7. Host cell entry is orchestrated by the viral spike protein
that, upon binding to ACE2, mediates fusion of the viral mem-
brane with the host membrane. The ectodomain of the heavily
glycosylated spike protein forms a trimer where each protomer
consists of a core S2 subunit and a distal S1 subunit. Each
S1 subunit comprises a receptor-binding domain (RBD) that can
switch between an exposed “up” conformation and a “down”
conformation, where the latter is inaccessible for ACE2 bind-
ing8–10. A number of antibodies against various viral surface
proteins are currently in clinical trials11. Exposed on the surface
of SARS-CoV-2, the spike protein is the major antigenic deter-
minant of the host immune response and one of the main cor-
onavirus drug targets12,13. Indeed, plasma from convalescent
SARS-CoV-2 patients was suggested to improve the clinical
outcome of patients with severe COVID-1914–16. Several groups
have isolated human antibodies that showed promising neu-
tralization activity against SARS-CoV-2 in vitro and improved
the clinical outcome of tested animals in vivo17–20. As an alter-
native to human antibodies, nanobodies (single-domain anti-
bodies) can also be used as therapeutics with the advantage of
their small size, increased stability, and superior simplicity in
production21,22. Recently, several groups showed that nano-
bodies can inhibit the binding of the spike protein to ACE2
and neutralize the virus23–25. Nanobodies are traditionally iso-
lated from immunized camelids; however, the development of
libraries of synthetic nanobodies (sybodies) enables a faster and
cheaper selection of binders against therapeutic targets26.
Here, we report the selection of sybodies directed against the
RBD of SARS-CoV-2 and demonstrate that they can compete
with ACE2 binding and neutralize SARS-CoV-2 spike pseudo-
virus. In particular, sybody 23 (Sb23) binds to recombinant RBD
as well as to the prefusion spike glycoprotein with high affinity
and shows very potent neutralization activity. A small angle X-ray
scattering (SAXS) model of a RBD–Sb23 complex indicated that
Sb23 binds in the vicinity of the ACE2-binding site on the RBD.
Lastly, a cryo-EM structure of Sb23 bound to the spike reveals
that Sb23 binds in the ACE2-binding site on the RBD in both its
“up” and “down” conformation and thereby effectively blocks
ACE2 binding. Interestingly, the cryo-EM reconstruction also
reveals that the spike bound to Sb23 displays an unusual con-
formation where two RBDs are in the “up” ACE2-binding
conformation.
Results
Sybody selection, ELISA and sequencing. Sybody selections on
biotinylated RBD were carried out with the three sybody libraries
(concave, loop and convex) following established procedures26,27.
The enrichment of binders against RBD was closely followed by
qPCR with enrichment factors of 100–9000 in the last selection
round, indicating strong specific enrichment (Fig. 1a). In general,
sybodies that gave rise to a positive ELISA signal for the RBD, did
so also for the prefusion spike protein. ELISA signals for the spike
protein were on average higher compared to the RBD, which
could be due to avidity effects caused by the trimeric nature of the
spike protein or an increased biotin density on the surface of the
protein. No binding to the negative control protein MBP was
observed for any of the binders, indicating RBD-specificity of the
selected sybodies (Supplementary Fig. 1). Next, we sequenced 100
clones which were positive in ELISA against RBD and spike
covering the three libraries equally well. We obtained 85 unique
sybody sequences (Supplementary Data 1). In total, 33 sybodies
were derived from the concave, 32 from the loop, and 20 from the
convex library. Based on sequence alignment and phylogenetic
tree analysis (Fig. 1b), it becomes clear that selected binders cover
a large sequence space.
Sybody purification and affinity analysis. 62 unique sybodies
were expressed in E. coli, purified via metal-affinity chromato-
graphy to high purity and characterized by analytical gel filtration
(Supplementary Fig. 2). We employed a biolayer interferometry
(BLI) assay to kinetically characterize the interaction of sybodies
with RBD. Biotinylated RBD was immobilized on a streptavidin
sensor and on- and off-rates for all purified sybodies were
determined at a single concentration (500 nM) yielding affinities
(KD) in a range of 5 nM–10 µM (Supplementary Fig. 3). Most
sybodies displayed strong binding signals, but many of them
exhibited fast off-rates, which is disadvantageous for neutraliza-
tion activity.
To obtain more accurate affinity data for RBD binding, we
selected sybodies 12, 23, 42, 76, 95, and 100 and determined their
binding constants by analyzing the on- and off-rates over a large
range of sybody concentrations. Resulting affinities are listed in
Fig. 2a–f. Tight binding of the selected binders to RBD was
further confirmed by thermal shift assays (Fig. 2g, h). In
particular, the interaction of Sb23 with RBD increases the
melting temperature of RBD by almost ten degrees, which is
considerably more than for other binders.
Sybodies neutralize SARS-CoV-2 spike pseudotyped viruses.
To test whether the selected sybodies can neutralize SARS-CoV-2,
we performed a neutralization assay with lentiviral particles
pseudotyped with the SARS-CoV-2 spike protein28. Thirty-six
sybodies were screened for neutralization, identifying eleven
capable of neutralizing SARS-CoV-2 at an IC50 < 20 µg/ml,
including six with an IC50 < 5 µg/ml (Supplementary Fig. 4a–c).
No neutralization of VSV-G pseudotyped viruses was evident for
any sybody preparation, and a control sybody targeting the
human peptide transporter 2 (PepT2) did not show any neu-
tralizing activity. Sybody 23 (Sb23) represented the most potent
sybody identified, with an IC50 of 0.6 µg/ml (Fig. 3a). The neu-
tralization efficiency of Sb23 was significantly increased by fusing
it to an antibody-derived Fc domain. The bivalent Sb23-Fc con-
structs, displays ~100-fold improved neutralization potential,
compared to its monovalent counterpart, with an IC50 of 0.007
µg/ml and an affinity towards the RBD in the pM range (Fig. 3a,
b). A similar effect was observed for Sb42-Fc (Supplementary
Fig. 4d, e).
Sb23 competes with ACE2 for RBD binding of the SARS-CoV-
2 spike protein. To obtain a deeper understanding of the neu-
tralizing activity of the identified binders, we performed BLI
assays to monitor ACE2 binding to immobilized RBD in the
presence or absence of Sb23. ACE2 bound RBD with an affinity of
33.4 nM under the stated experimental conditions, but no ACE2-
RBD binding was detected in the presence of 150 nM Sb23 over
the tested concentration range (Fig. 3c). This could be attributed
to either a direct competition for the receptor-binding motif, a
steric hindrance, or conformation induced changes upon Sb23
binding.
To confirm this observation in the context of the trimeric spike
protein, we developed a competition assay under equilibrium
conditions to screen binding of Sb23 to the spike protein in the
presence or absence of ACE2 using microscale thermophoresis.
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This method is sensitive to changes in size, charge state, and
hydration shell, and requires one binding partner to be
fluorescently labeled. We monitored binding of the fluorescently
labeled Sb23 to the spike protein in the presence of a constant
concentration of ACE2. In case the sybody targets a different
epitope on the RBD of the spike protein than ACE2, the resulting
affinity is expected to be independent of the presence of ACE2.
However, our data show that with increasing concentrations of
ACE2, the affinity of Sb23 to the spike protein drops 10-fold in
the presence of 200 nM ACE2 (Fig. 3d). In conclusion, these data
indicate that Sb23 and ACE2 compete for the same or
overlapping binding sites on SARS-CoV-2-RBD. At the same
time the data also highlight that Sb23 has a significantly higher
affinity to the RBD than ACE2 since Sb23 can efficiently replace
ACE2 from a preformed complex.
Characterization of Sb23 and RBD interaction by SAXS. To
shed light on the structural basis of the neutralization activity of
Sb23 against SARS-CoV-2, we collected SAXS on the RBD–Sb23
complex (Fig. 4a, b and Table 1). Complex formation is con-
firmed as judged by the shift of the position of the maximum in p
(r) and the increase of the particle size Dmax upon Sb23 binding.
The ab initio low-resolution shape depicts the Sb23 and RBD
moieties in the complex (Fig. 4c) and indicates that Sb23 is bound
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Fig. 1 Selection of sybodies against SARS-CoV-2 RBD. a Sybody selection statistics for the three different libraries. b Radial phylogenetic tree of all unique
binders identified in this study. Sequence alignment was performed using PROMAL3D and the phylogenetic tree was construct using the maximum
likelihood (ML) analysis in MEGA. Two sybodies (76 and 88), expected to stem from the convex library, were found to belong to the loop library,
presumably due to a spill-over during the selection procedure.
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To obtain a more detailed understanding, we performed SAXS-
based rigid body modeling of the complex between Sb23 and
RBD (Fig. 4d). The resulting hybrid rigid body model agrees well
with the ab initio shape of the complex (Fig. 4c) and, importantly,
in all resulting models, Sb23 is placed next to the ACE2-binding
site and binds sidewise to the RBD as expected for a binder from
the concave designed library.
Cryo-EM structure of the SARS-CoV-2 prefusion spike bound
to Sb23. To understand how Sb23 neutralizes SARS-CoV-2, we
determined the cryo-EM structure of spike bound to Sb23
(Fig. 5a, b). In the pool of particles that enabled a high-resolution
reconstruction, approximately half of the particles had one RBD
“up” (1-up) and the other half a conformation with two RBDs
“up” (2-up) (Fig. 6a and Supplementary Fig. 5). To the best of our
knowledge, the latter conformation has rarely been observed for
the SARS-CoV-2 prefusion spike but is commonly observed for
the MERS and SARS-1 spikes29,30.
In both main conformations and for both “up” and “down”
spike protomers, Sb23 binds in the inner edge of the ACE2
interaction interface of the RBD thereby effectively hindering
ACE2 binding (Fig. 6b). Modeling the ACE2-spike interaction
based on the ACE2-RBD crystal structure (6LZG31) of the soluble
part of ACE2 bound to SARS-CoV-2 RBD shows that Sb23
hinders binding of ACE2 in both the “1-up” and the “2-up”
conformation (Fig. 6b). Interestingly, ACE2 binding to the “up”
protomer is hindered in the “1-up” conformation also from Sb23
binding the neighboring “down” protomer (Fig. 6b). This
interprotomer-mediated blockage is true also for the correspond-
ing “up” protomer in the “2-up” conformation but not for the
2nd “up” protomer in this conformation. Hence, even if the
blockage of ACE2 binding in the “1-up” conformation from two
independent sites may contribute significantly to the efficacy in
neutralization by Sb23, the interprotomer-medicated blockage is
reduced in the “2-up” conformation.
Discussion
Currently there are no clinically validated vaccines or drugs
against SARS-CoV-2 available. Developing therapeutics is cur-
rently an ongoing worldwide effort and the identification of
neutralizing antibodies constitutes a key approach to that. Given
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Fig. 2 Biophysical characterization of identified sybodies. BLI sensorgrams of immobilized SARS-CoV-2 RBD with 2-fold serial dilution of 75 nM Sb23 (a),
188 nM Sb12 (b), 50 nM Sb42 (c), 250 nM Sb76 (d), 250 nM Sb95 (e), and 188 nM Sb100 (f). Binding curves are colored black and the global fit of the
data to a 1:1 binding model is red. Resulting affinities are indicated. g Thermal unfolding data of isolated RBD and in complex with Sb23. h Resulting melting
temperatures of RBD alone and in complex with Sb23, Sb76, Sb95, and a control sybody (NC), selected against the human peptide transporter (hPepT2).
Data represent the mean ± SD of three replicate experiments.
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research community has been trying to exploit innovative
methods and platforms for the development of vaccines or neu-
tralizing agents in the shortest possible time32. This methodology
is an attempt to minimize the overwhelming impact that SARS-
CoV-2 is having on the healthcare systems and to prepare for
future pandemics. Thus, the R&D community can act in a
prompter way for the development of efficient medication. Here
we demonstrate that it is possible to select highly specific binders
with neutralizing activity against SARS-CoV-2 from a synthetic
nanobody library in a timeframe of only 2–3 weeks. The tradi-
tional generation of nanobodies requires at least 6 weeks for the
Llama immunization and a total of 3–4 months for the entire
selection approach33. The sybody platform does not require any
immunization steps, has a large and diverse binder repertory in
order to account for the antibody maturation that naturally
occurs in vivo and only requires a fraction of the purified antigen
for the entire selection procedure27. The use of nanobodies as
therapeutic agents has been validated by the first nanobody drug
approved in 201934. Synthetic libraries could boost this new
technology in the establishment of platforms for the development
of nanobody-based drugs, with special importance in times that
fast methodologies are necessary.
In this work, we were able to identify 85 unique binders from a
single selection round. None of the unique sybodies identified in
this work were identical among two independent selections using
the same libraries35,36 thus highlighting the high diversity of the
three libraries and their potential for selecting several different
high-affinity binders. It should be noted that different constructs
of RBD and selection approaches were used for the independent
studies.
Six of our analyzed sybodies (Sb12, Sb23, Sb42, Sb76, Sb95, and
Sb100) bound RBD with affinities of 24.2, 10.6, 5.0, 58.1, 43.9, and
38.7 nM, respectively. The neutralization activity of the sybodies
was tested using lentiviral particles pseudotyped with the SARS-
CoV-2 spike protein. Sb23 was identified as the most potent
neutralizer with an IC50 of 0.6 µg/ml and 0.007 µg/ml for Sb23
and Sb23-Fc, respectively (Supplementary Table 1). Sb23 displays
higher affinity for SARS-CoV-2 RBD than the human receptor
ACE2 and competition assays suggest that Sb23 and ACE2
compete for the same or overlapping binding site. Based on initial
models for the RBD–Sb23 complex derived from SAXS data it
became clear that Sb23 binds next to the ACE2-binding site
causing a steric hindrance for ACE2 to bind.
A cryo-EM reconstruction of the spike revealed that Sb23
bound two conformations of the spike, one “1-up” and one “2-
up” conformation. The “2-up” conformation of the spike natu-
rally confers extra avidity with its two binding sites for ACE2.
We can at this stage only speculate if the binding of Sb23 itself
induces a conformational change that results in the “2-up” con-
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Fig. 3 Sb23 neutralizes SARS-CoV-2 pseudoviruses and competes with ACE2. a SARS-CoV-2 or VSV-G spike pseudotyped lentivirus was incubated with
a dilution series of Sb23, Sb23-Fc, or a control sybody (specific for hPepT2). Neutralization by Sb23 is a representative of two independent experiments.
Data are mean ± SD of six replicate experiments. Neutralization by Sb23-Fc represents two independent assays, performed in duplicates. Data are mean ±
SD of two or four replicate experiments. b BLI sensorgrams of immobilized SARS-CoV-2 RBD with 2-fold serial dilution of 20 nM Sb23-Fc. Binding curves
are colored black and the global fit of the data to a 1:1 binding model is red. c BLI sensorgrams of immobilized SARS-CoV-2 RBD with ACE2 in the presence
(blue) or absence (black) of 150 nM Sb23. The assay was performed in a concentration range of 200-12.5 nM ACE2 and fit of the data to a 1:1 binding
model is shown in red. d Microscale thermophoresis (MST) binding data of spike with fluorescently labeled Sb23, in the presence or absence of 200 nM
ACE2. One representative measurement is shown. Three independent measurements were performed and affinities of spike to Sb23 in the absence of
ACE2 ranged from 0.6 to 10 nM, while they were significantly lower in the presence of ACE2 (KD= 58–200 nM).
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the “2-up” in the spike’s dynamical landscape. Clearly, this con-
formation makes epitopes accessible for the development of
therapeutic binders in the central cavity of the spike, this includes
the lower portion of the RBD and possibly also the central helical
region. Hence, the use of Sb23-bound spike protein preparations
may be an excellent avenue to develop novel binders in these
regions. Furthermore, the cryo-EM reconstruction of Sb23-bound
spike will be crucial to develop either multimeric preparations of
Sb2337 with even increased affinity and neutralization ability or
structurally based combination therapy using Sb23 in combina-
tion with other neutralizing binders of different origin.
A cryo-EM complex, which became available while this work
was under review, between a traditional monoclonal FAB
(FAB_C105) and SARS-CoV2-Spike shows binding to both a “2-
up” and a “3-up” conformation38. Interestingly, FAB_C105 and
Sb23 bind at two different but partially overlapping regions on
the RBD (Supplementary Fig. 6). Sb23 binds on the outer RBD
surface that is opposite to the FAB_C105 RBD-binding site.
Thereby, Sb23 can bind the RBD in both “up” and “down”
conformation. On the other hand, FAB_C105 can only bind to
RBD in the “up” conformation since its binding site is not
available in the RBD down conformation as FAB_C105 is steri-
cally blocked by a neighboring FAB_C105 variable heavy chain
binding an RBD in the up conformation (Supplementary Fig. 6).
Arguably, this shows the strength of small high-affinity and
strongly neutralizing SARS-CoV-2 Spike binders such as the Sb23
in that they are not as often sterically occluded in the same
fashion as traditional much larger binders such as FABs.
Furthermore, among the sybodies that displayed IC50 values
below 20 µg/ml, we have identified a group of sybodies (Sb12, 76,
and 100) that can bind simultaneously with Sb23 to RBD and
were also able to abolish or decrease the binding affinity of ACE2
(Supplementary Fig. 7). For the development of therapeutic
agents, it would be advantageous to further increase the avidity
and affinity of these binders. Heterobivalent ligands are well
known in the pharmacology area, for their distinctly increased
avidity and residence time over the individual ligands39. By
combining the neutralization potential of Sb23 with a non-
overlapping sybody, we could potentially increase the overall
avidity towards the spike protein. Indeed, the bispecific chimeric
protein created by fusing Sb23 with Sb12 (Sb23/Sb12) displays
neutralization potential and affinity to RBD in the same range as
found for Sb23-Fc or Sb42-Fc (Supplementary Fig. 7g, h), high-
lighting the strength of such heterobivalent ligands.
The COVID-19 pandemic illustrates how previously unknown
viral strains can emerge and quickly spread across continents,
causing hundreds of thousands of fatalities in a very short time
period. The rapid fabrication of treatments against new viral
strains is a key component to prevent such fatality rates in the
future. Synthetic libraries are an alternative approach to rapid
drug development, quickly generating highly specific binders with
neutralization potential.
Methods
Construct design, expression, and purification of SARS-CoV-2 proteins. The
plasmid for the expression of the SARS-Cov2 prefusion-stabilized spike protein was
obtained by10. In short, the gene encodes residues 1–1208 of 2019-nCoV S
(GenBank: MN908947) with proline substitutions at residues 986 and 987, a
“GSAS” substitution at the furin cleavage site (residues 682–685), a C-terminal T4
fibritin trimerization motif, a HRV3C protease cleavage site, a Twin-Strep tag, an

























































Fig. 4 SAXS analysis of the Sb23–RBD complexes. a Experimental SAXS data from Sb23, RBD, and its complex. b Distance distribution functions of Sb23,
RBD, and their complex. c Two-phase MONSA shape of Sb23 (red beads) and RBD (blue beads). d Hybrid model of Sb23 in complex with RBD.
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residues (319–566) of 2019-nCoV RBD-SD1 and was cloned into a pαH mam-
malian expression vector containing a secretion signal, a C-terminal Sortase
recognition motif, and a non-cleavable Histidine tag25. Residues 1–616 of human
ACE2 including the native N-terminal secretion sequence (residues 1–17) were
cloned in a pXLG vector with a C-terminal HRV3C protease cleavage site and 2x
FLAG Flag tag for purification.
Suspension adapted HEK293-F cells were grown in 600-ml Bioreactors in
250 ml of serum-free FreeStyle medium in an incubator at 37 °C with humidified
atmosphere at 8% CO2 on an orbital shaker platform rotating at 220 rpm. Cells
were grown to a density of 0.4–3 × 106 cells/ml. Cell counts and viabilities were
determined by using standard Trypan blue exclusion methods in cell counter
(BioRad).
The spike and RBD constructs were transfected and expressed according to the
following protocol40. One day before transfection, cells were seeded in culture
medium at a density of 2 × 106 cells/ml. On the day of transfection, cells were
centrifuged (5 min, RT, 100 × g) and resuspended in fresh FreeStyle medium to a
final density of 20 × 106 cells/ml. DNA was added to a final concentration of 1.5
mg/l, mixed and followed by addition of MAX PEI in 1:2 ratio (w/w). Transfected
cells were incubated at 37 °C with agitation at 220 rpm in an 8% CO2 atmosphere
for 45 min. After this incubation time, fresh FreeStyle medium was added to reach
a final cell density of 1 × 106 cells/ml. Media with secreted proteins were harvested
4 days post-transfection (10,000 × g, 20 min, 4 °C) and filtered (pore size of
0.22 µm) prior purification.
For the ACE2 transfection, DNA was added to a final concentration of 0.75 µg/
106 cells, mixed and followed by the addition of Linear PEI 25 K in a 1:2 ratio (w/w).
The expression was conducted in glass flasks with an initial cell concentration of 2 ×
106 cells/ml in the presence of 2 mM sodium butyrate. Media containing the
secreted ACE2 protein was harvested 2 days post-transfection (1000 × g,
20 min, 4 °C).
SARS-CoV-2 prefusion spike for sybody selection, biophysical characterization,
and cryo-EM was expressed and purified as previously described25. For the
purification of the RBD domain, IMAC affinity chromatography was used41. To 1 l
of filtered medium imidazole was added to a final concentration of 15 mM.
Medium was loaded onto two 5 ml HisTrap™ High-performance columns
equilibrated with wash buffer (20 mM Na-P pH 7.4, 300 mM NaCl, 15 mM
imidazole), connected in tandem to the ÄKTAPure chromatography system using
a sample pump at a flow rate of 2 ml/min. Columns were washed with wash buffer
(20 mM Na-P pH 7.4, 300 mM NaCl, 15 mM imidazole) until the absorbance
reached a steady baseline. RBD was eluted in one-step with elution buffer (20 mM
Na-P pH 7.4, 150 mM NaCl, 300 mM imidazole). Eluted protein was concentrated
by ultrafiltration using Corning® Spin-X® UF concentrators with a cut-off limit of
10 kDa prior gel filtration. The concentrated protein sample was loaded on a
Superdex 200 Increase 10/300 GL column (GE Healthcare) equilibrated with GF
buffer (50 mM TRIS pH 7.4, 150 mM NaCl) using an ÄKTAPure chromatography
system. The elution profile was monitored at 280 nm and collected fractions
containing the target protein were concentrated to approximately 10 mg/ml, flash
frozen in liquid nitrogen and stored at −80 °C until further use.
For the ACE2 purification, the cell culture medium was mixed with 10×
washing buffer (500 mM TRIS pH 8.0, 1.5 M NaCl) and loaded onto M2 FLAG
beads. The beads were extensively washed with wash buffer (50 mM TRIS pH 8.0,
150 mM NaCl) and eluted with 3xFLAG peptide. The protein was further polished
by gel filtration on a Superdex 200 10/300 GL column in 50 mM HEPES pH 7.2,
150 mM NaCl, 10% glycerol, concentrated and flash frozen in liquid nitrogen until
further use.
All proteins were subject to quality control and initial biophysical
characterization (Supplementary Fig. 8).
Chemical biotinylation. The RBD and spike proteins were chemically biotinylated
using the EZ-Link NHS-PEG4-Biotin kit (Sigma). For the RBD, the sample was
first desalted using a PD-10 gravity flow column (GE Healthcare) in 20 mM Na-P
pH 7.4 and 150 mM NaCl. Subsequently, the sample was chemically biotinylated
for 2 h on ice, using a 20-fold molar excess of biotin over the target protein. The
spike sample was chemically biotinylated in a similar manner, using a 10-fold
molar excess of biotin for 1 h on ice. Both samples were further run on gel fil-
tration, following the protocol described above to remove non-reacted NHS-PEG4-
Biotin. The fractions containing the target protein were collected and concentrated
to approximately 1 mg/ml. 5% glycerol was added before flash-freezing, and the
samples were stored at −80 °C until further use.
Sybody selections, and ELISA. Sybody selections and ELISA were performed as
described in detail26,27. Sybody selections against biotinylated RBD were carried
out using three synthetic libraries diverging in the length of CDR3 loop, dubbed
concave, loop, and convex26. One round of ribosome display followed by two
rounds of phage display were performed. All rounds were monitored using qPCR.
To obtain binders with increased affinities, one off-rate selection was performed
during the second round of phage display, using 5 µM of non-biotinylated RBD
with a 5 min incubation time. Biotinylated maltose-binding protein (MBP) was
used as a negative control to determine the enrichment factor for each phage
display round. 94 individual colonies were randomly selected from each library and
cultured in TB medium for ELISA. The sybodies were expressed by inducing with
0.02% (w/v) L-Arabinose and the positive clones expressing RBD-specific sybodies
were identified by performing a periplasmic extraction and analyzed against the
two target proteins, biotinylated RBD and biotinylated spike. The same procedure
was performed for the MBP, used as background control signal.
Periplasmic extracts were transferred to microtiter plates, previously coated
with Protein A (Sigma), blocked in TBS-BSA buffer, and subsequently incubated
with anti-myc antibody (Sigma). After capturing the individual sybodies,
biotinylated target and control proteins were added at 50 nM concentration. The
last incubation step was performed by adding streptavidin-HRP (Sigma). Between
incubation steps, the plates were washed three times in TBS-BSA containing 0.05%
Tween-20. ELISA signals were developed by adding TMB (Sigma) in 50 mM
Na2HPO4, 25 mM citric acid and 0.006% H2O2. ELISA signals were measured at an
absorbance of 650 nm.
Cloning, expression, and purification of sybodies. The identified sybody genes of
positive clones were chemically transformed into Escherichia coli MC1061 F-
(Lucigen) cells. The cells were cultured in TB medium supplemented with chlor-
amphenicol (34 μg/mL) at 37 °C shaking at 200 rpm. Once the optical density
reached 0.4–0.8 (at 600 nm), the cultures were induced with the addition of 0.02%
(w/v) L-Arabinose and incubated at 22 °C, 200 rpm overnight. The proteins in the
periplasmic extract were released by osmotic shock and purified by immobilized
metal affinity chromatography (IMAC) using Ni-NTA resin (Invitrogen) in TBS
buffer (20 mM Tris, 150 mM NaCl, pH 7.4). The purified sybodies were desalted in
PBS (10 mM phosphate, 2.7 mM KCl and 137M NaCl, pH 7.4) buffer, analyzed by
SDS-PAGE and gel filtration using a SRT SEC-100 (Sepax Technologies) column.
For heterobivalent binding, Sb23 was fused with Sb12 via a G-S linker with a length
of 12 residues. The chimeric construct was expressed and purified in the same
manner as the other sybodies.
Sb23 or Sb42 were cloned into pCMVExt-Fc42 for mammalian expression, just
before the Fc domain from Human IgG. Transfection and expression of the Sb-Fc
constructs were performed as described before. The protein was purified from the
filtered media by immobilized metal affinity chromatography (IMAC) using Ni-
NTA resin (Invitrogen) in TBS buffer and desalted in PBS buffer. All primer
sequences used for preparation of the Sb or Fc fusion constructs can be found in
Supplementary Table 2.
Table 1 Data collection and structure statistics for SAXS
analysis.
Data collection parameters Sb23 RBD Sb23+RBD
Data collection parameters
Instrument EMBL P12 (PETRA III, DESY,
Hamburg)
Beam geometry (mm2) 0.2 × 0.12
Wavelength (nm) 0.124
s range (nm−1) 0.03–5.0
Exposure time (s) 4 (20 × 0.2 s)
Temperature (K) 293
Concentration range (mgml−1) 0.37–4.0
Structural parameters
Rg (nm) (from P(r)) 2.2 ± 0.1 3.2 ± 0.2 3.7 ± 0.2
Rg (nm) (from Guinier plot) 2.1 ± 0.1 3.1 ± 0.2 3.5 ± 0.2
Dmax (nm) 8.0 ± 0.5 13 ± 1 15 ± 1
Porod volume estimate, Vp
(nm3)
20 ± 2 66 ± 2 86 ± 5
Molecular weight determination (kDa)
From Porod volume (Vp/~1.6) 13 ± 1 37 ± 5 54 ± 3
From consensus Bayesian
assessment
15 ± 3 41 ± 1 53 ± 6





Primary data reduction SASFLOW SASFLOW SASFLOW
Data processing PRIMUS PRIMUS PRIMUS




3D graphics representations PYMOL PYMOL PYMOL
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Neutralization assay. Pseudotyped neutralization assays were adapted from
protocols previously validated to characterize the neutralization of HIV43, but with
the use of HEK293T-ACE2 cells as previously described25. Briefly, pseudotyped
lentiviruses displaying the SARS-CoV-2 spike protein (harboring an 18 amino acid
truncation of the cytoplasmic tail44) and packaging a luciferase reporter gene were
generated by the co-transfection of HEK293T cells. Media was changed 12–16 h
after transfection, and pseudotyped viruses were harvested at 48- and 72-h post-
transfection, filtered through a 0.45 µm filter, and stored at −80 °C until use.
Pseudotyped viruses sufficient to generate ~100,000 RLUs were incubated with
serial dilutions of sybodies for 60 min at 37 °C, and then ~15,000 HEK293T-ACE2
cells were added to each well. Plates were incubated at 37 °C for 48 h, and lumi-
nescence was measured using Bright-Glo (Promega) on a GM-2000 luminometer
(Promega).
Thermal stability assays. The thermal stability of RBD, ACE2, and spike was
monitored by nanoDSF (NanoTemper Technologies) at a concentration of
0.25 mg/ml in PBS (10 mM phosphate, 2.7 mM KCl and 137M NaCl, pH 7.4)
buffer. To monitor binding-induced thermal shift changes of the RBD with dif-
ferent sybodies, RBD at 0.25 mg/ml was incubated with 0.15 mg/ml of different
sybodies (Sb23, Sb76, Sb95, control Sb) and incubated for at least 10 min at RT
prior analysis. Standard grade nanoDSF capillaries (NanoTemper Technologies)
were loaded into a Prometheus NT.48 device (NanoTemper Technologies) con-
trolled by PR. ThermControl (version 2.1.2). Excitation power was adjusted to 30%
and samples were heated from 20 °C to 90 °C with a slope of 1 °C/min. All samples
were run in triplicates and error bars represent standard deviations. The stability of
the different sybodies was analyzed in independent experiments and they all dis-
play transition temperatures in the range of 70–95 °C.
Far-UV CD spectroscopy. RBD, spike protein, and ACE2 were dialyzed or diluted
by the buffer containing 10 mM Na-P (pH 7.5) and 20 mM NaCl to 0.11, 0.13, and
0.08 mg/ml, respectively. The CD spectrum was measured on a Chirascan CD
spectrometer (Applied Photophysics) in a 0.1 mm cuvette between 195 and 260 nm
with 1 nm steps ten times. The resulting spectra were averaged, buffer-subtracted
and the secondary structure was estimated by the K2D algorithm using
Dichroweb45.
Biolayer interferometry (BLI). The binding of selected sybodies to RBD or
binding of RBD to ACE2 proteins was measured by biolayer interferometry (BLI)
using the Octet RED96 system (FortéBio).
For the RBD-binding screening assay, biotinylated RBD was loaded on
streptavidin biosensors (FortéBio), pre-equilibrated in assay buffer (PBS-buffer
supplemented with 0.5% (w/v) BSA and 0.05% (v/v) Tween-20) for 20 min. Prior to
association, a baseline step of 60 s was performed. Subsequently, sensors were
dipped in a well containing 500 nM target sybody (association step) for 10 min
followed by 15 min of dissociation time in the same buffer.
Concentration-dependent kinetic assays were performed in a similar manner,
by dipping RBD-captured streptavidin biosensors in different concentrations of
target protein (sybodies 23, 42, 76, and 95 or ACE2) ranging from 5 to 250 nM for
8 min followed by a 12 min dissociation step. Competition assays of RBD-ACE2
with Sb23 were performed in an identical manner, containing 150 nM final
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Fig. 5 Cryo-EM reconstruction of SARS-CoV-2 spike bound to Sb23. a Locally sharpened Coulomb potential map and cartoon model of Sb23 bound to the
spike protein in the “1-up” conformation and cartoon model of Sb23-bound spike. b Locally sharpened Coulomb potential map and cartoon model of Sb23
bound to the spike protein in the “2-up” conformation.
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Data were reference-subtracted and aligned with each other in the Octet Data
Analysis software v10.0 (FortéBio), using a 1:1 binding model. All figures were
prepared using Prism 8 (GraphPad).
Microscale thermophoresis (MST). The binding affinity of spike to Sb23 was
measured by microscale thermophoresis using the MST NT.115 device (NanoTemper
Technologies). Sb23 was labeled via the His6-tag with RED-tris-NTA dye (Nano-
Temper Technologies) in PBS-T (10mM phosphate, 2.7mM KCl and 137M NaCl,
pH 7.4 supplemented with 0.05% (v/v) Tween-20), following the manufacturer’s
instructions. A 2-fold dilution series of spike protein was prepared in PBS-T with the
highest concentration in the assay being 1250 nM. A 50 nM final concentration of
labeled Sb23 was mixed with the substrate dilution series and incubated for 10min at
room temperature before loading the samples in standard capillaries. For the com-
petition assay, the same procedure was used but the spike dilution series were pre-
pared in PBS-T buffer containing 800 nM of ACE2 (200 nM final concentration in the
assay) and incubation of 10min prior to mixing with labeled Sb23. All measurements
were performed in triplicate using 35% LED and medium MST power. The data were
analyzed using the MO. Affinity Analysis software (NanoTemper Technologies).
Figures were prepared using Prism 8 (GraphPad).
Small angle X-ray scattering measurements (SAXS). The SAXS data were
collected at the EMBL P12 beamline of the storage ring PETRA III (DESY,
Hamburg, Germany) using a robotic sample changer46. The scattering from the
protein solutions and respective solvents was recorded on a Pilatus-6M pixel
detector, radially averaged and processed using standard procedures. For all con-
structs, a concentration series was measured in the range of about 0.3–4 mg/ml and
the data were extrapolated to infinite dilution as needed. The radial average was
performed and solvent scattering was subtracted using the SASFLOW pipeline47.
The distance distributions were computed by GNOM48 and the overall parameters
were determined from the reduced data using relevant programs from the ATSAS
suite47. The ab initio low-resolution shapes were restored using the program
MONSA49. Scattering from the high-resolution models was computed by CRY-
SOL50. Hybrid models of the sybodies and of the RBD were constructed by
CORAL51 using the available high-resolution portions as rigid bodies and
amending them by chains of dummy residues to represent the fragments not
present in the crystal. For RBD, three glycans were added to the most frequent
relative abundance of glycan species, the C-terminal portion was modeled as a coil,
and the structure was refined using SREFLEX52. The model of Sb23–RBD complex
was constructed using the rigid body modeling program SASREF53.
Cryo-EM sample preparation and Imaging. Spike trimer (0.7 mg/ml) and Sb23
(1.3 mg/ml) were mixed in a 1:3 molar ratio and incubated on ice for 5 min. A 3-μl
aliquot of the sample solution was applied to glow-discharged CryoMatrix holey
grids with amorphous alloy film (Zhenjiang Lehua Technology) in a Vitrobot Mk
IV (Thermo Fisher Scientific) at 4 °C and 100% humidity (blot 10 s, blot force 3).
Cryo-EM data collection was performed with EPU 2.7 (Thermo Fisher Scientific)
using a Krios G3i transmission-electron microscope (Thermo Fisher Scientific)
operated at 300 kV in the Karolinska Institutet 3D-EM facility. Images were
acquired in nanoprobe EFTEM mode with a slit width of 10 eV using a Bio-
Quantum K3 (Ametek) during 1.5 s with a flux of 8.7 e−/px/s resulting in a fluence
of 50 e−/Å2 equally fractionated into 60 frames. Motion correction, CTF-estima-
tion, Fourier binning (to 1.02 Å/px), particle picking, and extraction were per-
formed on the fly using Warp54. A total of 8,236 micrographs that fulfilled the
required criteria (defocus less than 2 microns and estimated resolution better than
4 Å) were selected and 387,116 particles were picked by Warp. Extracted particles
were imported into cryoSPARC v2.15.055 for 2D classification, heterogenous
refinement, and non-uniform 3D refinement56. The particles were processed with
C1 symmetry throughout. After 2D classification (300 classes) 199,501 particles
were retained and used to build three ab initio 3D reconstructions. These were
further processed for heterogeneous refinement that resulted in one reconstruction
showing high-resolution structural features in the core of the spike. After one
round of homogenous refinement we performed 3D variability analysis using three
orthogonal principle modes. In the ensuing analysis, we separated out four dif-
ferent clusters of which two gave clusters that showed clearly contrasting recon-
structions after separate homogenous reconstructions (“1-up” and “2-up”). These
two reconstructions were then used together with two “crap” classes in high-
resolution heterogeneous refinement of the original particle set selected from 2D
classification. The overall resolution of the “1-up” and “2-up” conformations using
non-uniform refinement56 is 3.1 Å and 2.9 Å (0.143 FSC) using 70,854 and 69,567
particles, respectively. The local resolution of the density in the very top of the
spike is lower (Supplementary Fig. 5). All processing and local resolution plotted
on the electron density surface are shown in Supplementary Fig. 5 and recon-
struction and refinement details are found in Table 2.
Model building and structure refinement. A Cryo-EM structure of the SARS-
CoV-2 spike protein trimer10 (PDB: 6VSB) was used as a starting model for model
building. The model was extended and manually adjusted in COOT57. The sybody
structure was homology modeled using Phyre258 with PDB: 4PFE59 as a template.
The missing regions of the RBD domains were built based on the RBD-spike crystal


























Fig. 6 Top view of cryo-EM reconstruction of SARS-CoV-2 spike bound to Sb23 and modeling of the structural basis for Sb23-based blockage of SARS-
CoV-2 spike binding to ACE2. a Top view of locally sharpened Coulomb potential map and cartoon model of Sb23 bound to the spike protein in the “1-up”
conformation b Top view of locally sharpened Coulomb potential map and cartoon model of Sb23 bound to the spike protein in the “2-up” conformation.
c Cartoon model of Sb23-bound Spike in the “1-up” (left) “2-up” (right) conformation showing how ACE2 binding is blocked by Sb23 bound to the RBD in
the “up” conformation as well as Sb23 bound to the neighboring RBD in the down conformation.
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performed using COOT and PHENIX60 in interspersed cycles with secondary
structure and geometry restrained. All structure figures and all EM density-map
figures were generated with UCSF ChimeraX61.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The scattering data and models of Sb23, RBD and their complex are deposited into
SASBDB (www.sasbdb.org), entries SASDJF4, SASDJG4 and SASDJH4 respectively. The
MST and BLI data are available under https://github.com/tania-custodio/Sb23. The cryo-
EM density maps of SARS-CoV-2 spike glycoprotein with Sb23 bound were deposited in
the Electron Microscopy Data Bank (EMDB) with accession codes EMD-11616 (1-up)
and EMD-11617 (2-up). The corresponding models were deposited in the Protein Data
Bank (PDB) with accession codes 7A25 (1-up) and 7A29 (2-up). The sequences of all the
selected sybodies from this study are provided in Supplementary Data 1. Any other
experimental data that support the findings of this study are available from the
corresponding authors upon request. Source data are provided with this paper.
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